Beijing Sun Novo Pharmaceutical Research Co Ltd Asset Resilience Ratio
Beijing Sun Novo Pharmaceutical Research Co Ltd asset resilience ratio. Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) has an Asset Resilience Ratio of 2.04% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Beijing Sun Novo Pharmaceutical Research fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Beijing Sun Novo Pharmaceutical Research Co Ltd (2021–2025)
Asset resilience ratio of Beijing Sun Novo Pharmaceutical Research Co Ltd from 2021 to 2025. This chart shows how Beijing Sun Novo Pharmaceutical Research Co Ltd's Asset Resilience Ratio has changed over time. Read 688621 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Beijing Sun Novo Pharmaceutical Research Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Beijing Sun Novo Pharmaceutical Research total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥47.00 Million | 2.04% |
| Total Liquid Assets | CN¥47.00 Million | 2.04% |
Asset Resilience Insights
- Limited Liquidity: Beijing Sun Novo Pharmaceutical Research Co Ltd maintains only 2.04% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Beijing Sun Novo Pharmaceutical Research Co Ltd Industry Peers by Asset Resilience Ratio
Compare Beijing Sun Novo Pharmaceutical Research Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Porton Fine Chemicals Ltd
SHE:300363 |
Drug Manufacturers - Specialty & Generic | 6.85% |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA |
Drug Manufacturers - Specialty & Generic | 1.26% |
Beijing Sun Novo Pharmaceutical Research Co Ltd Asset Resilience Ratio by Year (2021–2025)
Beijing Sun Novo Pharmaceutical Research Co Ltd asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for Beijing Sun Novo Pharmaceutical Research Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.28% | CN¥75.00 Million ≈ $10.97 Million |
CN¥2.28 Billion ≈ $334.34 Million |
+1.77pp |
| 2024-12-31 | 1.51% | CN¥30.00 Million ≈ $4.39 Million |
CN¥1.99 Billion ≈ $290.81 Million |
-0.10pp |
| 2023-12-31 | 1.61% | CN¥30.00 Million ≈ $4.39 Million |
CN¥1.86 Billion ≈ $272.62 Million |
+0.71pp |
| 2022-12-31 | 0.90% | CN¥13.11 Million ≈ $1.92 Million |
CN¥1.46 Billion ≈ $214.10 Million |
-11.79pp |
| 2021-12-31 | 12.68% | CN¥157.60 Million ≈ $23.06 Million |
CN¥1.24 Billion ≈ $181.84 Million |
-- |
About Beijing Sun Novo Pharmaceutical Research Co Ltd
Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of drugs in China. The company operates an external preparation platform that focuses on the research and development of new drugs and generic drugs for skin external preparations; children's clinical data bridging research center; pediatric drug research and development platfo… Read more